Handelsbanken Fonder
VRDN icon

Handelsbanken Fonder’s Viridian Therapeutics VRDN Stock Holding History

Handelsbanken Fonder’s Portfolio VRDN Stock Details VRDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$834K Buy
+45,400
New +$731K ﹤0.01% 1218

Other funds holding VRDN

HWAM
Hennion & Walsh Asset Management Parsippany, New Jersey $3.5B AUM 41.95% 1-Year Est. Return
YIH
Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return
DA
Doliver Advisors Houston, Texas $442M AUM 34.09% 1-Year Est. Return
EC
Eleva Capital Paris, France $343M AUM
GI
GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return
FFA
Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return
VCM
Versant Capital Management Phoenix, Arizona $1.12B AUM 34.21% 1-Year Est. Return
LI
LRI Investments Palm Beach Gardens, Florida $1.24B AUM 11.13% 1-Year Est. Return
TM
Torren Management San Diego, California $197M AUM

Handelsbanken Fonder's VRDN Position: Q2 2026 in Review

Handelsbanken Fonder opened a new position in Viridian Therapeutics (VRDN) in Q2 2026: 45,400 shares worth $834K. The stake represents ﹤0.01% of the portfolio and ranks #1218 among its holdings.

10 funds tracked by Wall St. Rank hold VRDN as of Q2 2026.

  • Handelsbanken Fonder held 45,400 shares of Viridian Therapeutics worth $834K as of Q2 2026.
  • Viridian Therapeutics was a new Handelsbanken Fonder position in Q2 2026.
  • Viridian Therapeutics made up ﹤0.01% of Handelsbanken Fonder's portfolio in Q2 2026, its #1218 holding.
  • 10 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q2 2026.

Based on Handelsbanken Fonder's 13F filing for Q2 2026, filed 10 Jul 2026.